04:21 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Adhesion targets emerge at ASH 2018

The next wave of targets in blood cancers and hematology will come from adhesion molecules, innate immune cells and regulators of gene expression, according to BioCentury’s analysis of emerging targets at ASH 2018. BioCentury’s analysis...
07:00 , Aug 19, 2013 |  BC Week In Review  |  Clinical News

Argos, Danaher preclinical data

In a mouse model of high-risk cornea transplant, topical administration of sCD83 via eye drops prolonged graft survival. Data were published in the Journal of Immunology. Argos has exclusive rights from Beckman Coulter Inc. to...
07:00 , May 16, 2011 |  BC Week In Review  |  Clinical News

Argos, Beckman Coulter preclinical data

In a mouse model of heart transplantation, sCD83 decreased intragraft B cell infiltration and significantly increased cardiac allograft survival vs. untreated controls (16 vs. 8 days, p=0.01). Data were presented at the American Transplant Congress...
07:00 , Apr 30, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Renal disease

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Renal disease Renal disease; renal damage Dendritic cells (DCs) A study in mice and in cell culture suggests that targeting proinflammatory...
07:00 , Mar 16, 2009 |  BC Week In Review  |  Clinical News

Argos, Beckman Coulter preclinical data

In mouse models of kidney transplantation, sCD83 prevented transplant rejection, achieved long-term graft tolerance, significantly improved survival and inhibited development of anti-donor antibodies compared with untreated kidney graft recipients. In mouse models of heart transplantation,...
08:00 , Feb 19, 2009 |  BC Innovations  |  Cover Story

Dendritic cell depletion for acute GvHD

Although many companies in the graft-versus-host disease space are targeting the T cells responsible for destroying host tissues, an Australian research group has moved upstream and developed an antibody that attacks the cells responsible for...
08:00 , Feb 12, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Transplantation

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Transplantation Graft-versus-host disease (GvHD) CD83 A study in mice suggests that depleting activated dendritic cells (DCs) may be useful for treating and...
07:00 , Aug 7, 2008 |  BC Innovations  |  Targets & Mechanisms

Avoiding TB's subversion

Mycobacterium tuberculosis has proven a tough bug to tame, with no effective vaccines on the market to stop the bacterium's spread. Now, a study published in the Proceedings of the National Academy of Sciences describes...
07:00 , May 14, 2007 |  BC Week In Review  |  Clinical News

Argos, Beckman Coulter preclinical data

In mice with heart transplants, monotherapy with sCD83 produced graft survival of 15 days vs. 8.3 days for control animals. Animals receiving sCD83 plus anti-CD45RB MAb and rapamycin had graft survival of >100 days. Data...
07:00 , May 15, 2006 |  BioCentury  |  Tools & Techniques

Turning T cells off

Argos Therapeutics Inc. says CD83 , the therapeutic protein it recently in-licensed from Beckman Coulter Inc. , may serve as a switch that turns off autoimmunity. The company is completing preclinical testing of the molecule...